MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Galectin Therapeutics Company Profile (NASDAQ:GALT)

Consensus Ratings for Galectin Therapeutics (NASDAQ:GALT) (?)
Ratings Breakdown: 4 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $12.00 (705.37% upside)

Analysts' Ratings History for Galectin Therapeutics (NASDAQ:GALT)
Show:
DateFirmActionRatingPrice TargetActions
5/19/2016FBR & Co.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/12/2016HC WainwrightReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/8/2016Roth CapitalReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/12/2015MLV & Co.Reiterated RatingBuy$16.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/1/2014AegisDowngradeBuy -> HoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/29/2014BMO Capital MarketsReiterated RatingPositiveView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/29/2014 forward)
Earnings History for Galectin Therapeutics (NASDAQ:GALT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/8/2016        
5/10/2016Q1($0.17)($0.24)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/15/2016Q415($0.22)($0.19)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/9/2015Q3($0.20)($0.26)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/10/2015Q2($0.23)($0.21)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/11/2015Q115($0.20)($0.22)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/18/2015($0.17)($0.18)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2014Q314($0.27)($0.17)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/2014Q214($0.21)($0.17)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/13/2014Q114($0.20)($0.27)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/21/2014($0.18)($0.15)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2013Q3($0.18)($0.22)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/14/2013Q213($0.19)($0.18)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/10/2013Q1 2013($0.18)($0.22)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/9/2012Q312($0.18)($0.19)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Galectin Therapeutics (NASDAQ:GALT)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.22)($0.22)($0.22)
Q2 20162($0.24)($0.22)($0.23)
Q3 20162($0.25)($0.22)($0.24)
Q4 20162($0.24)($0.22)($0.23)
Q1 20171($0.22)($0.22)($0.22)
Q2 20171($0.22)($0.22)($0.22)
Q3 20171($0.22)($0.22)($0.22)
Q4 20171($0.22)($0.22)($0.22)
(Data provided by Zacks Investment Research)
Dividend History for Galectin Therapeutics (NASDAQ:GALT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Galectin Therapeutics (NASDAQ:GALT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
1/5/2016Arthur GreenbergDirectorBuy1,666$1.72$2,865.52View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/12/2015Peter G TraberCEOBuy2,000$2.00$4,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/1/2015Kevin D FreemanDirectorBuy2,083$2.70$5,624.10View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/1/2015Peter G TraberCEOBuy4,000$2.53$10,120.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/19/2014Arthur GreenbergDirectorBuy1,000$4.56$4,560.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/15/2014Kevin D FreemanDirectorBuy1,000$4.70$4,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/14/2014Jack W CallicuttCFOBuy1,000$4.55$4,550.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/14/2014Peter G TraberCEOBuy4,000$4.46$17,840.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/13/2014Peter G TraberCEOBuy1,000$4.42$4,420.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/11/2014Steven PrelackDirectorSell6,000$11.84$71,040.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/13/2014James C CzirrChairmanSell100,000$14.84$1,484,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/4/2013Marc RubinDirectorBuy3,000$8.69$26,070.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/19/2013Arthur GreenbergDirectorBuy2,000$6.55$13,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/19/2013Peter G TraberCEOBuy1,000$5.53$5,530.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/18/2013Peter G TraberCEOBuy1,000$5.80$5,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/15/2013James C CzirrChairmanBuy1,000$6.90$6,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/3/2013John F MauldinDirectorBuy1,176$4.21$4,950.96View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/28/2013Kevin D FreemanDirectorBuy1,000$4.21$4,210.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/12/2012Peter G TraberCEOBuy2,500$2.11$5,275.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/9/2012Peter G TraberCEOBuy2,500$2.00$5,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/8/2012Peter G TraberCEOBuy5,000$2.07$10,350.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Galectin Therapeutics (NASDAQ:GALT)
DateHeadline
06/26/16 03:40 PMShare Volatility Check for: Galectin Therapeutics, Inc. (NASDAQ:GALT) - Press Telegraph
06/26/16 03:40 PMStrong Sell Calls Recommendations For Galectin Therapeutics Inc. (NASDAQ:GALT) At 0 - Investor Newswire
06/26/16 03:40 PMGalectin Therapeutics Inc. (GALT) Jumps 6.9% on June 24 - Equities.com
06/23/16 07:04 AMGalectin Therapeutics Inc. (GALT) Updated Price Targets - FTSE News
06/21/16 03:53 PMThis Weeks Broker Views For Galectin Therapeutics Inc. (GALT) - Fiscal Standard
06/20/16 03:58 PMGALECTIN THERAPEUTICS INC : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)
06/20/16 03:32 PMGALECTIN THERAPEUTICS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exh -
06/19/16 08:29 AMStrong Buy Calls Count For Galectin Therapeutics Inc. (NASDAQ:GALT) At 2 - Investor Newswire
06/16/16 04:10 PMRecently Issued Stock Ratings For Galectin Therapeutics Inc. (GALT) - Fiscal Standard
06/06/16 09:35 PMPNM Resources, Inc. (NYSE:PNM) Increased 1.84%: Galectin Therapeutics, Inc. (NASDAQ:GALT), AbbVie Inc. (NYSE ... - KC Register
06/02/16 04:22 PMGalectin Therapeutics (GALT) Announces Positive GR-MD-02 Preclinical Data in PAH - StreetInsider.com - Galectin Therapeutics (GALT) Announces Positive GR-MD-02 Preclinical Data in PAHStreetInsider.comGalectin Therapeutics, Inc. (Nasdaq: GALT) reports that GR-MD-02, its development-stage galectin-3 (gal-3) inhibitor, has shown a positive effect on vascular remodeling in an animal model of pulmonary arterial hypertension (PAH). The results were ...Galectin Therapeutics Reports Positive Preclinical Results on GR-MD-02 For Pulmonary Arterial Hypertension ...Sonoran Weekly Reviewall 3 news articles »
06/02/16 07:15 AMGalectin Therapeutics Announces Positive Preclinical Results on the Role of Galectin-3 in Mediating Vascular Remodeling in Pulmonary Arterial Hypertension - [at noodls] - NORCROSS, Ga., June 02, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, reports that ...
05/31/16 04:17 PMStrong Sell Calls Count For Galectin Therapeutics Inc. (NASDAQ:GALT) At 0 - Investor Newswire - Strong Sell Calls Count For Galectin Therapeutics Inc. (NASDAQ:GALT) At 0Investor NewswireGalectin Therapeutics Inc. (NASDAQ:GALT) has a total of 2 Strong Buy calls and 0 Strong Sell advises as of 2016-05-30. Zacks uses a rating procedure which assigns scores to stocks on a narrow 1-5 scale. When a stock gets a score of 1 or 2, it is ...and more »
05/29/16 12:04 AMGalectin Therapeutics Incorporated (NASDAQ:GALT) Sellers Increased By 5.45% Their Shorts - HNN - Galectin Therapeutics Incorporated (NASDAQ:GALT) Sellers Increased By 5.45% Their ShortsHNNThe short interest to Galectin Therapeutics Incorporated's float is 3.18%. The stock increased 4.96% or $0.07 on May 27, hitting $1.48. About 39,233 shares traded hands. Galectin Therapeutics Inc (NASDAQ:GALT) has declined 46.38% since October 22, ...After Recent Decline, is it Time to Sell Galectin Therapeutics, Inc. (NASDAQ:GALT)Franklin Independentall 2 news articles »
05/23/16 12:17 PMAfter Last Week What Do Analysts Think Of Galectin Therapeutics Inc. (GALT) - Share Trading News - After Last Week What Do Analysts Think Of Galectin Therapeutics Inc. (GALT)Share Trading News10/07/2013 – Ascendiant Capital Markets began new coverage on Galectin Therapeutics Inc. giving the company a “buy” rating. They now have a USD 13 price target on the stock. The share price of Galectin Therapeutics Inc. (GALT) was down -0.65% during ...
05/20/16 06:58 PMRevenue Update on Galectin Therapeutics Inc(NASDAQ:GALT) - Trade Calls - Revenue Update on Galectin Therapeutics Inc(NASDAQ:GALT)Trade CallsGalectin Therapeutics Inc(NASDAQ:GALT) announced the earnings results for Fiscal Year 2016 and Q1. The results came in during After-hours on May 10, 2016. Earnings per share were $-0.24. Analysts had estimated an EPS of $-0.17. In a different note, On ...Galectin Therapeutics Inc. (GALT) Updated Broker Price TargetsShare Trading NewsGalectin Therapeutics Incorporated (NASDAQ:GALT) Sellers Covered 6.83% of Their ShortsWall Street Hints and NewsAnalysts Offer Insights on Healthcare Companies: Galectin Therapeutics (GALT) (NASDAQ: GALT), Mazor Robotics ...Analyst Ratingsall 4 news articles »
05/19/16 06:59 PMGalectin Therapeutics Incorporated (NASDAQ:GALT) Sellers Covered 6.83% of Their Shorts - Wall Street Hints and News - Galectin Therapeutics Incorporated (NASDAQ:GALT) Sellers Covered 6.83% of Their ShortsWall Street Hints and NewsThe short interest to Galectin Therapeutics Incorporated's float is 3.11%. The stock is up 5.44% or $0.08 after the news, hitting $1.55 per share. About 88,050 shares traded hands. Galectin Therapeutics Inc (NASDAQ:GALT) has declined 43.24% since ...Analysts Offer Insights on Healthcare Companies: Galectin Therapeutics (GALT) (NASDAQ: GALT), Mazor Robotics ...Analyst Ratingsall 2 news articles »
05/19/16 12:04 PMGALECTIN THERAPEUTICS INC Financials -
05/18/16 11:26 AMNanocap Volatile Stocks: Galectin Therapeutics (NASDAQ:GALT), NovaBay Pharmaceuticals (NYSEMKT:NBY ... - KC Register - Nanocap Volatile Stocks: Galectin Therapeutics (NASDAQ:GALT), NovaBay Pharmaceuticals (NYSEMKT:NBY ...KC RegisterGalectin Therapeutics, Inc. (NASDAQ:GALT) announces positive interim results from an exploratory, open-label, Phase 2a clinical trial with GR-MD-02 in patients with moderate-to-severe plaque psoriasis. All four patients who received 12 weeks of therapy ...and more »
05/16/16 06:43 PMGalectin Therapeutics (GALT) Offers Positive Update from GR-MD-02 Phase 2a - StreetInsider.com - Galectin Therapeutics (GALT) Offers Positive Update from GR-MD-02 Phase 2aStreetInsider.comGalectin Therapeutics Inc. (NASDAQ: GALT) announces positive interim results from an exploratory, open-label, Phase 2a clinical trial with GR-MD-02 in patients with moderate-to-severe plaque psoriasis. All four patients who received 12 weeks of therapy ...and more »
05/16/16 04:24 PM5:24 pm Galectin Therapeutics announces 'positive' interim results from Phase 2a clinical trial with GR-MD-02 -
05/16/16 03:22 PMGalectin Therapeutics Announces Positive Interim Results from Phase 2a Trial with GR-MD-02 in Moderate-to-Severe Plaque Psoriasis - [at noodls] - A significant clearing of psoriasis in first four patients prompts the extension of treatment for an additional 12 weeks Conference call to be held tomorrow at 9:00 a.m. Eastern time NORCROSS, Ga., May ...
05/14/16 12:32 AMEnrollment in NASH-FX trial for advanced fibrosis, NASH complete - Galectin Therapeutics Inc. announced enrollment is complete for its phase 2 NASH-FX trial investigating GR-MD-02, a complex carbohydrate drug that targets galectin-3, for the treatment of nonalcoholic steatohepatitis and advanced fibrosis. The study ...
05/13/16 12:52 AMGalectin Therapeutics Inc. (GALT) Jumps 11.59% on May 11 - Equities.com - Galectin Therapeutics Inc. (GALT) Jumps 11.59% on May 11Equities.comGalectin Therapeutics Inc. (GALT) was among the biggest gainers on the Russell 2000 for Wednesday May 11 as the stock popped 11.59% to $1.54, representing a gain of $0.16 per share. Some 197,357 shares traded hands on 513 trades, compared with an ...and more »
05/11/16 07:43 PMGalectin Therapeutics (GALT) Completes Enrollment in Phase 2 Trial with GR-MD-02 in NASH - StreetInsider.com - Galectin Therapeutics (GALT) Completes Enrollment in Phase 2 Trial with GR-MD-02 in NASHStreetInsider.comGalectin Therapeutics Inc. (NASDAQ : GALT) announces the completion of enrollment in its Phase 2 clinical trial with GR-MD-02 in patients with non-alcoholic steatohepatitis (NASH) with advanced fibrosis (stage 3) (the NASH-FX trial). The Company ...Top News: Galectin Therapeutics, Inc. (NASDAQ:GALT), Nautilus Inc. (NYSE:NLS), Newmont Mining Corporation ...KC RegisterGalectin Therapeutics Completes Enrollment for Trial of GR-MD-02 in Fibrosis Patients; Shares Jump 16% Early ...Sonoran Weekly ReviewGalectin Therapeutics hits enrollment target in mid-stage NASH study of lead product candidate, top-line data ...Seeking Alphaall 5 news articles »
05/11/16 07:52 AMGalectin Therapeutics Announces Complete Enrollment in its Phase 2 Trial with GR-MD-02 in NASH Patients with Advanced Fibrosis - [at noodls] - NORCROSS, Ga., May 11, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announces the ...
05/11/16 06:52 AMGALECTIN THERAPEUTICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits -
05/10/16 07:28 PMGalectin Therapeutics Inc. (GALT) Jumps 9.52% on May 10 - Equities.com - Galectin Therapeutics Inc. (GALT) Jumps 9.52% on May 10Equities.comGalectin Therapeutics Inc. (GALT) was among the biggest gainers on the Russell 2000 for Tuesday May 10 as the stock popped 9.52% to $1.38, representing a gain of $0.1199 per share. Some 112,841 shares traded hands on 317 trades, compared with an ...Galectin Therapeutics Inc. (GALT) Latest Broker CoverageRisers & FallersGalectin Therapeutics Incorporated (NASDAQ:GALT) Short Interest Decreased By 16.46%Franklin IndependentGalectin Therapeutics Inc.: Galectin Therapeutics Reports First Quarter 2016 Financial Results and Provides Business ...The Wall Street TranscriptSonoran Weekly Reviewall 5 news articles »
05/10/16 08:41 AMBRIEF-Galectin Therapeutics Inc qtrly loss per share $0.24 - * Believes it has sufficient cash to fund currently planned operations, research and development activities through march 31, 2017
05/10/16 07:18 AMGalectin Therapeutics Reports First Quarter 2016 Financial Results and Provides Business Update - [at noodls] - NORCROSS, Ga., May 10, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today reported ...
05/10/16 06:53 AMGALECTIN THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and -
05/10/16 06:51 AMGALECTIN THERAPEUTICS INC Files SEC form 10-Q, Quarterly Report -
05/06/16 01:30 AMPortal Hypertension Therapeutics Drugs and Companies Pipeline Market H1 2016 - Portal Hypertension - Companies Involved in Therapeutics Development: Conatus Pharmaceuticals Inc. Galectin Therapeutics, Inc. Gilead Sciences, Inc. Intercept Pharmaceuticals, Inc. LinXis B.V. Mezzion Pharma Co. Ltd. Ono Pharmaceutical Co., Ltd. Featured ...
05/05/16 07:11 AMPreclinical Research on the Role of Galectin-3 in Pulmonary Arterial Hypertension to be Presented at the American Thoracic Society 2016 International Conference - [at noodls] - NORCROSS, Ga., May 05, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, has received ...
05/03/16 07:15 PMThis Weeks Broker Price Targets For Galectin Therapeutics Inc. (GALT) - Share Trading News - SmallCap NetworkThis Weeks Broker Price Targets For Galectin Therapeutics Inc. (GALT)Share Trading NewsThey now have a USD 8 price target on the stock. 03/09/2016 – Roth Capital began new coverage on Galectin Therapeutics Inc. giving the company a “buy” rating. 08/12/2015 – Galectin Therapeutics Inc. had its “buy” rating reiterated by analysts at MLV & Co.Galectin Therapeutics (GALT) Pushes Past the Point of No ReturnSmallCap NetworkGalectin Therapeutics Inc. (NASDAQ:GALT) 50-day MA At $1.473RealistInvestor.comall 3 news articles »
05/03/16 07:15 PMGalectin Therapeutics Inc. (GALT) Drops 7.04% on May 02 - Equities.com - Galectin Therapeutics Inc. (GALT) Drops 7.04% on May 02Equities.comGalectin Therapeutics Inc. (GALT) was one of the Russell 2000's biggest losers for Monday May 02 as the stock slid 7.04% to $1.32, a loss of $-0.1 per share. Starting at an opening price of $1.44 a share, the stock traded between $1.30 and $1.44 over ...and more »
05/02/16 08:55 PMGalectin Therapeutics Inc. (NASDAQ:GALT) 50-day MA At $1.473 - RealistInvestor.com - SmallCap NetworkGalectin Therapeutics Inc. (NASDAQ:GALT) 50-day MA At $1.473RealistInvestor.comAs per the technical analysis, Galectin Therapeutics Inc. (NASDAQ:GALT) stock is trading $-0.126 away -8.563% from 50-day MA of $1.473, and $-0.397 or -22.747% away 200-day MA of $1.744. Discounting today's price, the stock's price is $-2.763 off ...This Weeks Broker Price Targets For Galectin Therapeutics Inc. (GALT)Share Trading NewsGalectin Therapeutics (GALT) Pushes Past the Point of No ReturnSmallCap Networkall 3 news articles »
04/29/16 07:46 PMGalectin Therapeutics Inc. (NASDAQ:GALT) Basic Consolidated EPS At $-0.8303 - Stocks Daily - Galectin Therapeutics Inc. (NASDAQ:GALT) Basic Consolidated EPS At $-0.8303Stocks DailyThe basic per-share earnings from continuing operations as confirmed by Galectin Therapeutics Inc. (NASDAQ:GALT) for the period closed 2015-12-31 was $-0.8303. For the quarter ended 2015-12-31, this number was $-0.8303. For any specified company's ...
04/29/16 07:46 PMGalectin Therapeutics Inc. (GALT) Drops 7.01% on April 28 - Equities.com - Galectin Therapeutics Inc. (GALT) Drops 7.01% on April 28Equities.comGalectin Therapeutics Inc. (GALT) was one of the Russell 2000's biggest losers for Thursday April 28 as the stock slid 7.01% to $1.46, a loss of $-0.11 per share. Starting at an opening price of $1.57 a share, the stock traded between $1.45 and $1.57 ...and more »
04/28/16 08:53 PMBroker Outlook For Galectin Therapeutics Inc. (GALT) - Share Trading News - Broker Outlook For Galectin Therapeutics Inc. (GALT)Share Trading NewsThe Company has two compounds in development GRMD02 and GMCT01 both of which have shown promise in preclinical studies in treatment of fibrosis and in cancer therapy. The Company is focusing on the development of GRMD02 intended to be used ...
04/26/16 07:20 PMBroker Roundup For Galectin Therapeutics Inc. (GALT) - Share Trading News - Broker Roundup For Galectin Therapeutics Inc. (GALT)Share Trading News10/07/2013 – Ascendiant Capital Markets began new coverage on Galectin Therapeutics Inc. giving the company a “buy” rating. They now have a USD 13 price target on the stock. The share price of Galectin Therapeutics Inc. (GALT) was up +0.00% during ...Galectin Therapeutics Incorporated (NASDAQ:GALT) Short Interest Decreased By 3.12%The Postall 3 news articles »
04/25/16 02:57 AM5 Top NASDAQ Biotech Stocks: Eleven Biotherapeutics Soars 159 Percent - Last week Hansen Medical entered into an acquisition agreement with Auris Surgical Robotics, Inc., in which Auris will acquire ... investors will find Galectin Therapeutics. The company is engaged in pursuing therapies for indications in which galectins ...
04/22/16 09:03 PMGalectin Therapeutics Inc. (GALT) is Trading Lower on Unusual Volume for April 20 - Equities.com - Galectin Therapeutics Inc. (GALT) is Trading Lower on Unusual Volume for April 20Equities.comGalectin Therapeutics Inc. (GALT) experienced unusually high volume on Apr. 20, as the stock lost 10.3% to a closing price of $1.48. The stock saw 272,719 shares trade hands over the course of the day on 771 trades. Given that the stock's average daily ...and more »
04/21/16 08:59 PMGalectin Therapeutics Inc. (GALT) Drops 10.3% on April 20 - Equities.com - Galectin Therapeutics Inc. (GALT) Drops 10.3% on April 20Equities.comGalectin Therapeutics Inc. (GALT) was one of the Russell 2000's biggest losers for Wednesday April 20 as the stock slid 10.3% to $1.48, a loss of $-0.17 per share. Starting at an opening price of $1.65 a share, the stock traded between $1.46 and $1.65 ...and more »
04/21/16 01:53 AMGalectin Therapeutics Inc. (GALT) is Trading Lower on Unusual Volume for April 19 - Equities.com - Galectin Therapeutics Inc. (GALT) is Trading Lower on Unusual Volume for April 19Equities.comGalectin Therapeutics Inc. (GALT) experienced unusually high volume on Apr. 19, as the stock lost 1.79% to a closing price of $1.65. The stock saw 306,312 shares trade hands over the course of the day on 660 trades. Given that the stock's average daily ...and more »
04/20/16 02:44 AMGalectin Therapeutics Inc. (GALT) is Trading Higher on Unusual Volume for April 18 - Equities.com - Galectin Therapeutics Inc. (GALT) is Trading Higher on Unusual Volume for April 18Equities.comGalectin Therapeutics Inc. (GALT) experienced unusually high volume on Apr. 18, as the stock gained 0.6% to a closing price of $1.68. The stock saw 384,906 shares trade hands over the course of the day on 1,094 trades. Given that the stock's average ...and more »
04/15/16 08:46 PMGalectin Therapeutics Inc. (GALT) Jumps 10.6% on April 15 - Equities.com - Galectin Therapeutics Inc. (GALT) Jumps 10.6% on April 15Equities.comGalectin Therapeutics Inc. (GALT) was among the biggest gainers on the Russell 2000 for Friday April 15 as the stock popped 10.6% to $1.67, representing a gain of $0.16 per share. Some 362,851 shares traded hands on 1,461 trades, compared with an ...and more »
03/15/16 07:00 AMGalectin Therapeutics Reports 2015 Financial Results and Provides Business Update - [GlobeNewswire] - NORCROSS, Ga., March 15, 2016-- Galectin Therapeutics Inc., the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today reported financial results for the year ...
03/08/16 03:09 PMGalectin Therapeutics to Hold Business Update Conference Call on March 15 - [GlobeNewswire] - NORCROSS, Ga., March 08, 2016-- Galectin Therapeutics, Inc., the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announces that in conjunction with the filing ...
03/07/16 03:00 PMGalectin Therapeutics to Present at the 28th Annual ROTH Conference - [GlobeNewswire] - NORCROSS, Ga., March 07, 2016-- Galectin Therapeutics, Inc., the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announces today Peter G. Traber, M.D., the ...
About Galectin Therapeutics

Galectin Therapeutics logoGalectin Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company's drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions. It uses naturally occurring, readily-available plant materials as starting material in manufacturing processes to create complex carbohydrates with specific molecular weights and other pharmaceutical properties. The Company has two product candidates, GR-MD-02 and GM-CT-01. The Company's galectin-3 inhibitor is GR-MD-02. The Company is focusing on development of GR-MD-02 intended to be used in the treatment of liver fibrosis associated with fatty liver disease (NASH), moderate to severe plaque psoriasis and in cancer therapy in combination with immune-system modifying agent(s). GM-CT-01 is a compound that continues to be explored in preclinical studies.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Drugs - Generic
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: GALT
  • CUSIP:
Key Metrics:
  • Previous Close: $1.49
  • 50 Day Moving Average: $1.46
  • 200 Day Moving Average: $1.43
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $43.18M
  • Current Quarter EPS Consensus Estimate: $-0.97 EPS
Additional Links:
Galectin Therapeutics (NASDAQ:GALT) Chart for Wednesday, June, 29, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha